RxDoctor Payments Data

Ashleigh Thompson, MD

Cardiovascular Disease · Charlotte, NCNPI 1275777179

Payments from drug & device makers

$2,431in general payments, 2019–2025

Across 74 payments — averaging $32.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$444
  • Boston Scientific$310
  • Cvrx, Inc.$251
  • Amgen$230
  • Impulse Dynamics (USA) Inc.$171
  • Bayer$167
  • plus $858 from 15 others

What the payments were for

  • Food & beverage$2,431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,431 in reported general payments places this provider in the 45th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$61,749
Medicare patients
311
Services billed
576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban193$226,768
EntrestoSacubitril/Valsartan49$74,038
XareltoRivaroxaban19$30,379
Repatha SureclickEvolocumab19$16,775
Praluent PenAlirocumab11$9,227
Metoprolol Succinate154$2,516
Atorvastatin Calcium232$2,175
Rosuvastatin Calcium149$1,917
Diltiazem 24hr Er (Cd)Diltiazem Hcl62$1,378
Potassium Chloride58$1,235
Furosemide167$1,081
Amlodipine Besylate140$961
Flecainide Acetate30$905
Carvedilol103$849
Torsemide23$773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$226,768193 claims
NovartisEntresto$146$74,03849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →